


BIOSYNTHETIC STUDIES OF  
TERPENTECIN

Sir:

In a previous paper<sup>1)</sup> we reported the structure of terpentecin (1)<sup>2)</sup>, a diterpenoid antitumor antibiotic produced by the strain MF730-N6 classified as a *Kitasatosporia* species. Here we wish to report a labeling study of terpentecin with [5-<sup>13</sup>C]mevalonolactone and sodium [2-<sup>13</sup>C]-acetate. The result supported the structure previously reported<sup>1)</sup>.

A 500-ml Erlenmeyer flask containing 110 ml of the seed medium (pH 7.2) composed of glucose 1% and yeast extract 1% was inoculated with strain MF730-N6 and the culture was grown at 27°C for 24 hours on a rotary shaker. A 3-ml portion of the seed culture thus prepared was used to inoculate each 500-ml Sakaguchi

Fig. 1. The structure of terpentecin (1) and its derivative (2).



Terpentecin (1) X = O                      R = H  
2                      X = CHCOOCH<sub>3</sub>      R = pBrBz


Table 1. Chemical shifts and incorporation of [2-<sup>13</sup>C]acetate and [5-<sup>13</sup>C]mevalonolactone.

Carbon atom	Chemical shift <sup>a</sup> (ppm)	Normalized peak height <sup>b</sup>	
		[2- <sup>13</sup> C]-Acetate	[5- <sup>13</sup> C]-Mevalonolactone
1	207.8	1.4	4.6
2	77.1	3.9	1.5
3	41.4	1.7	1.4
4	38.9	2.0	1.5
5	41.1	2.1	1.3
6	19.3	3.0	1.6
7	26.1	1.7	4.1
8	124.4	2.9	2.5
9	137.8	2.1	1.7
10	51.8	2.3	1.7
11	40.2	1.4	5.2
12	67.7	3.7	1.2
13	63.8	1.0	1.0
14	49.1	2.7	2.0
15	146.4	1.9	2.2
16	136.8	1.6	5.4
3-CH <sub>3</sub>	11.2	2.4	2.3
4-CH <sub>3</sub>	24.2	2.4	2.7
9-CH <sub>3</sub>	20.6	2.8	2.6
10-CH <sub>3</sub>	23.8	2.8	2.9

<sup>a</sup> Measured in CDCl<sub>3</sub> solution, in ppm down field from internal TMS. Spectra were recorded on a Jeol GX-400 spectrometer. Signal assignment were reported in ref 1.

<sup>b</sup> Intensity of each peak was normalized based on the peak intensity at the C-13 position as standard.

Scheme 1.



flask containing 125 ml of medium (glucose 0.04%, galactose 0.08%, maltose 0.08%, dextrin 0.16%, Bacto-soytone 0.08% and ammonium sulfate 0.03%, pH 7.0). Fermentation was carried out for 28 hours at 27°C.  $^{13}\text{C}$ -Labeled precursors were added after 0 and 6 hours incubation. The dose per flask was 2 mg for  $[5\text{-}^{13}\text{C}]$ mevalonolactone and 10 mg for  $[2\text{-}^{13}\text{C}]$ acetate. The  $^{13}\text{C}$ -labeled terpentecin was isolated from the culture filtrate and converted chemically to the stable form **2** as reported in a previous paper<sup>1)</sup> (Fig. 1).

As shown in the  $^{13}\text{C}$  NMR spectrum (Table 1), the signal intensities of the carbon atoms C-1, -7, -11 and -16 of  $[5\text{-}^{13}\text{C}]$ mevalonolactone-labeled compound **2** were increased approximately 5-fold. This result indicates that terpentecin (which has a clerodane skeleton<sup>3)</sup>) is biosynthesized from 4 molecules of mevalonate *via* geranyl-geranyl pyrophosphate<sup>4)</sup> as illustrated in Scheme 1.

The incorporation rates of  $[5\text{-}^{14}\text{C}]$ mevalonate and  $[U\text{-}^{14}\text{C}]$ acetate were 1.8% and 0.1% (data is not shown). Probably due to the low incorporation, the values of normalized peak height in the  $^{13}\text{C}$  NMR spectrum of the terpentecin derivative (**2**)  $^{13}\text{C}$ -enriched from  $^{13}\text{C}$ -acetate should include a rather large error variation. However, the  $^{13}\text{C}$  NMR spectrum of  $[2\text{-}^{13}\text{C}]$ acetate-derived terpentecin derivative (**2**) showed twelve enhanced peaks corresponding to C-2, -4, -6, -8, -10, -12, -14, -15, 3- $\text{CH}_3$ , 4- $\text{CH}_3$ , 9- $\text{CH}_3$  and 10- $\text{CH}_3$ . This labeling pattern also supported the biosynthetic route, *via* mevalonate and geranyl-geranyl pyrophosphate.

KUNIO ISSHIKI  
TSUYOSHI TAMAMURA  
TSUTOMU SAWA  
HIROSHI NAGANAWA  
TOMIO TAKEUCHI  
HAMA O UMEZAWA

Institute of Microbial Chemistry,  
3-14-23 Kamiosaki, Shinagawa-ku,  
Tokyo 141, Japan

(Received June 4, 1986)

#### References

- 1) ISSHIKI, K.; T. TAMAMURA, Y. TAKAHASHI, T. SAWA, H. NAGANAWA, T. TAKEUCHI & H. UMEZAWA: The structure of a new antibiotic, terpentecin. *J. Antibiotics* 38: 1819~1821, 1985
- 2) TAMAMURA, T.; T. SAWA, K. ISSHIKI, T. MASUDA, Y. HOMMA, H. IINUMA, H. NAGANAWA, M. HAMADA, T. TAKEUCHI & H. UMEZAWA: Isolation and characterization of terpentecin, a new antitumor antibiotic. *J. Antibiotics* 38: 1664~1669, 1985
- 3) ANDERSEN, N. R.; H. O. B. LORCK & P. R. RASMUSSEN: Fermentation, isolation and characterization of antibiotic PR-1350. *J. Antibiotics* 36: 753~760, 1983
- 4) ACKLAND, M. J.; J. R. HANSON & A. H. RATCLIFFE: Studies in terpenoid biosynthesis. Part 30. The acetate and mevalonate labelling patterns of the diterpenoid. *Aphidicidin. J. Chem. Soc. Perkin Trans I.* 1984: 2751~2754, 1984